Free Trial

AstraZeneca PLC (NASDAQ:AZN) Given Average Rating of "Buy" by Analysts

AstraZeneca logo with Medical background

Shares of AstraZeneca PLC (NASDAQ:AZN - Get Free Report) have received an average recommendation of "Buy" from the ten research firms that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and two have issued a strong buy rating on the company. The average 12-month target price among brokerages that have covered the stock in the last year is $88.00.

A number of brokerages recently commented on AZN. BNP Paribas began coverage on AstraZeneca in a research note on Tuesday, April 15th. They issued an "outperform" rating and a $75.00 price target for the company. Morgan Stanley began coverage on AstraZeneca in a research note on Wednesday, February 12th. They issued an "overweight" rating for the company. Finally, UBS Group raised AstraZeneca from a "neutral" rating to a "buy" rating in a research note on Thursday, February 13th.

Check Out Our Latest Stock Report on AstraZeneca

Hedge Funds Weigh In On AstraZeneca

A number of institutional investors have recently added to or reduced their stakes in AZN. Lindbrook Capital LLC increased its holdings in shares of AstraZeneca by 1.9% during the first quarter. Lindbrook Capital LLC now owns 7,574 shares of the company's stock valued at $557,000 after acquiring an additional 141 shares in the last quarter. Cibc World Markets Corp increased its holdings in shares of AstraZeneca by 1.1% during the fourth quarter. Cibc World Markets Corp now owns 12,901 shares of the company's stock valued at $845,000 after acquiring an additional 142 shares in the last quarter. Principal Securities Inc. increased its holdings in shares of AstraZeneca by 0.5% during the first quarter. Principal Securities Inc. now owns 28,053 shares of the company's stock valued at $2,062,000 after acquiring an additional 142 shares in the last quarter. Sage Mountain Advisors LLC increased its holdings in shares of AstraZeneca by 3.4% during the first quarter. Sage Mountain Advisors LLC now owns 4,478 shares of the company's stock valued at $329,000 after acquiring an additional 147 shares in the last quarter. Finally, CoreCap Advisors LLC increased its holdings in shares of AstraZeneca by 31.8% during the fourth quarter. CoreCap Advisors LLC now owns 642 shares of the company's stock valued at $42,000 after acquiring an additional 155 shares in the last quarter. Institutional investors own 20.35% of the company's stock.

AstraZeneca Trading Up 0.6%

Shares of NASDAQ:AZN traded up $0.40 during trading on Monday, reaching $70.78. 2,267,853 shares of the company traded hands, compared to its average volume of 5,168,370. The firm has a market capitalization of $219.49 billion, a price-to-earnings ratio of 31.31, a P/E/G ratio of 1.42 and a beta of 0.40. AstraZeneca has a 52-week low of $61.24 and a 52-week high of $87.68. The company has a current ratio of 0.93, a quick ratio of 0.74 and a debt-to-equity ratio of 0.65. The business's fifty day moving average is $69.45 and its 200-day moving average is $69.58.

AstraZeneca (NASDAQ:AZN - Get Free Report) last announced its quarterly earnings results on Tuesday, April 29th. The company reported $1.24 EPS for the quarter, topping analysts' consensus estimates of $1.10 by $0.14. AstraZeneca had a return on equity of 32.23% and a net margin of 13.01%. The company had revenue of $13.59 billion during the quarter, compared to analyst estimates of $13.71 billion. During the same quarter last year, the firm posted $2.06 earnings per share. The firm's revenue was up 7.2% on a year-over-year basis. As a group, analysts forecast that AstraZeneca will post 4.51 EPS for the current year.

About AstraZeneca

(Get Free Report

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.

Featured Stories

Analyst Recommendations for AstraZeneca (NASDAQ:AZN)

Should You Invest $1,000 in AstraZeneca Right Now?

Before you consider AstraZeneca, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.

While AstraZeneca currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA Earnings Preview: HUGE Stock Move Ahead
These 5 Small Stocks Could Deliver Huge Returns
ACT FAST! Congress Is POURING Into This Stock

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines